DR. DATSONS LABS | IPCA LABS | DR. DATSONS LABS/ IPCA LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -10.9 | 21.5 | - | View Chart |
P/BV | x | 0.2 | 7.7 | 2.1% | View Chart |
Dividend Yield | % | 0.0 | 0.2 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. DATSONS LABS Mar-14 |
IPCA LABS Mar-19 |
DR. DATSONS LABS/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 1,042 | 12.1% | |
Low | Rs | 31 | 590 | 5.2% | |
Sales per share (Unadj.) | Rs | 133.0 | 298.6 | 44.5% | |
Earnings per share (Unadj.) | Rs | 0.2 | 35.0 | 0.4% | |
Cash flow per share (Unadj.) | Rs | 6.6 | 49.4 | 13.4% | |
Dividends per share (Unadj.) | Rs | 0 | 3.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 128.8 | 247.1 | 52.1% | |
Shares outstanding (eoy) | m | 31.66 | 126.35 | 25.1% | |
Bonus/Rights/Conversions | FCCB | ESOS | - | ||
Price / Sales ratio | x | 0.6 | 2.7 | 21.5% | |
Avg P/E ratio | x | 516.1 | 23.3 | 2,213.6% | |
P/CF ratio (eoy) | x | 11.8 | 16.5 | 71.7% | |
Price / Book Value ratio | x | 0.6 | 3.3 | 18.4% | |
Dividend payout | % | 0 | 8.6 | 0.0% | |
Avg Mkt Cap | Rs m | 2,477 | 103,108 | 2.4% | |
No. of employees | `000 | NA | 13.4 | 0.0% | |
Total wages/salary | Rs m | 56 | 7,874 | 0.7% | |
Avg. sales/employee | Rs Th | NM | 2,807.0 | - | |
Avg. wages/employee | Rs Th | NM | 585.8 | - | |
Avg. net profit/employee | Rs Th | NM | 329.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,211 | 37,732 | 11.2% | |
Other income | Rs m | 79 | 577 | 13.6% | |
Total revenues | Rs m | 4,289 | 38,309 | 11.2% | |
Gross profit | Rs m | 569 | 6,901 | 8.2% | |
Depreciation | Rs m | 204 | 1,824 | 11.2% | |
Interest | Rs m | 430 | 189 | 228.0% | |
Profit before tax | Rs m | 13 | 5,465 | 0.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | -2 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6 | 1,042 | 0.6% | |
Profit after tax | Rs m | 5 | 4,422 | 0.1% | |
Gross profit margin | % | 13.5 | 18.3 | 73.8% | |
Effective tax rate | % | 48.0 | 19.1 | 251.8% | |
Net profit margin | % | 0.1 | 11.7 | 1.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,852 | 23,778 | 28.8% | |
Current liabilities | Rs m | 6,711 | 10,975 | 61.1% | |
Net working cap to sales | % | 3.3 | 33.9 | 9.9% | |
Current ratio | x | 1.0 | 2.2 | 47.1% | |
Inventory Days | Days | 161 | 104 | 155.0% | |
Debtors Days | Days | 318 | 66 | 483.1% | |
Net fixed assets | Rs m | 3,673 | 20,368 | 18.0% | |
Share capital | Rs m | 317 | 253 | 125.3% | |
"Free" reserves | Rs m | 3,761 | 30,971 | 12.1% | |
Net worth | Rs m | 4,078 | 31,224 | 13.1% | |
Long term debt | Rs m | 1,671 | 1,409 | 118.6% | |
Total assets | Rs m | 12,633 | 45,507 | 27.8% | |
Interest coverage | x | 1.0 | 30.0 | 3.4% | |
Debt to equity ratio | x | 0.4 | 0 | 908.4% | |
Sales to assets ratio | x | 0.3 | 0.8 | 40.2% | |
Return on assets | % | 3.4 | 10.1 | 34.0% | |
Return on equity | % | 0.1 | 14.2 | 0.8% | |
Return on capital | % | 7.7 | 17.3 | 44.3% | |
Exports to sales | % | 22.9 | 45.9 | 49.9% | |
Imports to sales | % | 14.3 | 16.6 | 86.1% | |
Exports (fob) | Rs m | 964 | 17,308 | 5.6% | |
Imports (cif) | Rs m | 602 | 6,266 | 9.6% | |
Fx inflow | Rs m | 964 | 17,308 | 5.6% | |
Fx outflow | Rs m | 607 | 6,266 | 9.7% | |
Net fx | Rs m | 357 | 11,042 | 3.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,345 | 4,923 | 27.3% | |
From Investments | Rs m | -2,256 | -1,563 | 144.3% | |
From Financial Activity | Rs m | -1,200 | -1,832 | 65.5% | |
Net Cashflow | Rs m | -2,111 | 1,528 | -138.2% |
Indian Promoters | % | 4.5 | 45.9 | 9.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 11.4 | - | |
FIIs | % | 1.4 | 25.3 | 5.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 94.1 | 17.4 | 540.8% | |
Shareholders | 20,807 | 36,892 | 56.4% | ||
Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare DR. DATSONS LABS With: DIVIS LABORATORIES WOCKHARDT VENUS REMEDIES PANACEA BIOTECH GLENMARK PHARMA
Compare DR. DATSONS LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.
For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
In this video, I'll show you how to get started on the path to daily trading profits.
More